Weight-loss jabs, such as Ozempic, Wegovy and Mounjaro, have quickly earned a glowing global reputation for shifting the ...

In a novel theory, scientists at Arizona State University's Biodesign Institute propose a unifying explanation for the ...

The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.

Vadim Stroykin, 58, became the latest Russian to take a suspiciously timed nosedive out of a high window as police performed ...